5-Fluorouracil + Oxaliplatin + Leucovorin + Irinotecan + Gemcitabine + Nab Paclitaxel
Phase 2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 36/100
36
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Pancreatic Ductal Adenocarcinoma
Conditions
Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma
Trial Timeline
Sep 9, 2025 → Sep 30, 2030
NCT ID
NCT07096362About 5-Fluorouracil + Oxaliplatin + Leucovorin + Irinotecan + Gemcitabine + Nab Paclitaxel
5-Fluorouracil + Oxaliplatin + Leucovorin + Irinotecan + Gemcitabine + Nab Paclitaxel is a phase 2 stage product being developed by BillionToOne for Metastatic Pancreatic Ductal Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07096362. Target conditions include Metastatic Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Pancreatic Ductal Adenocarcinoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07096362 | Phase 2 | Recruiting |
Competing Products
20 competing products in Metastatic Pancreatic Ductal Adenocarcinoma